Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2201 - Immunomodulation by regorafenib alone and in combination with anti PD1 antibody on murine models of colorectal cancer


10 Sep 2017


Poster display session


Cytotoxic Therapy;  Cancers in Adolescents and Young Adults (AYA);  Cancer Biology;  Immunotherapy;  Colon and Rectal Cancer


Sabine Hoff


Annals of Oncology (2017) 28 (suppl_5): v403-v427. 10.1093/annonc/mdx376


S. Hoff1, S. Grünewald2, L. Röse1, D. Zopf2

Author affiliations

  • 1 Oncology Iii, Bayer AG, 13353 - Berlin/DE
  • 2 Oncology Ii, Bayer AG, 13353 - Berlin/DE


Abstract 2201


Regorafenib is a small molecule inhibitor of multiple kinases involved in normal cellular functions and in pathologic processes such as oncogenesis, angiogenesis, and tumor immunity. Regorafenib is approved for the treatment of advanced colorectal cancer (CRC) and gastrointestinal stromal tumors. In addition, an overall survival benefit has recently been shown in patients with hepatocellular carcinoma who had previously progressed on sorafenib (RESORCE trial). Immuno-oncology treatment strategies have recently expanded the arsenal of highly effective cancer therapies. In addition to their activity in monotherapy, they are being tested in combination with other therapies, including those inhibiting angiogenesis, to further improve their antitumor activity. We investigated the immunomodulatory effect of regorafenib alone and in combination with a mouse-reactive anti PD1 antibody in mouse models of CRC.


CT26 or MC38 syngeneic tumors were treated with regorafenib alone and in combination with anti PD1. We monitored tumor growth and analyzed the immune status of tumors ex vivo at the end of the study. Immune infiltrates were characterized by flow cytometry, intratumoral cytokines by multiplex ELISA, and expression of immunologically relevant genes by qPCR.


Both regorafenib and anti PD1 inhibited the growth of MC38 tumors vs control, and this effect was significantly enhanced by concomitant treatment or when regorafenib was given after anti PD1. Regorafenib treatment most consistently reduced tumor-infiltrating macrophages in both MC38 and CT26 tumors in a dose-dependent manner. Additionally, signs of M1-type macrophage conversion were detected by elevated inducible NO synthase and reduced arginase expression. This may be due to a regorafenib-mediated inhibition of the CSF1 receptor, as shown in vitro in the murine macrophage cell line RAW264.7. Anti PD1 treatment was associated with elevated interferon-g levels, indicative of enhanced T cell activation.


These results warrant further exploration of a combination of regorafenib and PD1 for the treatment of colorectal cancer.

Clinical trial identification

Legal entity responsible for the study

Bayer AG


Bayer AG


S. Hoff, S. Grünewald, L. Röse, D. Zopf: Employees of Bayer AG, and some are shareholders of Bayer AG stocks.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.